Clarity Pharmaceuticals Ltd
ASX CU6.AX
Clarity Pharmaceuticals Ltd Price to Sales Ratio (P/S) on January 14, 2025: 98.37
-
Clarity Pharmaceuticals Ltd 52-week high Price to Sales Ratio (P/S) is 251.15 on October 02, 2024, which is 155.30% above the current Price to Sales Ratio (P/S).
-
Clarity Pharmaceuticals Ltd 52-week low Price to Sales Ratio (P/S) is 61.66 on January 16, 2024, which is -37.32% below the current Price to Sales Ratio (P/S).
-
Clarity Pharmaceuticals Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is 139.39.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Ms. Michelle Parker |
| IPO Date | Aug. 25, 2021 |
| Location | Australia |
| Headquarters | National Innovation Centre |
| Employees | 50 |
| Sector | Health Care |
| Industries | |
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
Past 5 years
USD 0.68
USD 15.47
StockViz Staff
January 15, 2025
Any question? Send us an email